Physician profile
Robert D Mcquaid
NPI 1386627693
$3,635.95
in general payments reported to CMS, 2019-2025
16 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $92.76 · 2021: $165 · 2022: $363 · 2023: $772 · 2024: $970 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $746.68 | 2019-2024 | Dailies, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $717.83 | 2022-2025 | Infuse, Biotrue, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $359.08 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $316.38 | 2019-2024 | |
| Glaukos Corporation | $297.86 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $238.16 | 2024 | Syfovre |
| Abbvie INC. | $179.99 | 2022-2023 | |
| Abb Con-Cise Optical Group LLC | $158.53 | 2019 | |
| Hoffmann-La Roche Limited | $140.40 | 2019 | |
| Ocular Therapeutix, INC. | $123.20 | 2024 | Dextenza |
| Astellas Pharma US INC | $114.06 | 2024 | Izervay |
| Genzyme Corporation | $113.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.39 | 2022 | |
| Kala Pharmaceuticals, INC. | $29.89 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $18.79 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcquaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.